Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes

Publication date: Available online 12 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jonathan E. Brammer, Dai Chihara, L. Michelle Poon, Paolo Caimi, Marcos de Lima, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Michele Fanale, Bouthaina Dabaja, Richard T. Maziarz, Richard E. Champlin, Chitra Hosing, Yasuhiro Oki
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hayder Saeed, Lubomir Sokol
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Leyla Bojanini, Liuyan Jiang, Alexander J. Tun, Ernesto Ayala, David M. Menke, Bradford Hoppe, Mohamed A. Kharfan-Dabaja, Han W. Tun, Muhamad Alhaj Moustafa
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Pierluigi Porcu, Stacie Hudgens, Steven Horwitz, Pietro Quaglino, Richard Cowan, Larisa Geskin, Marie Beylot-Barry, Lysbeth Floden, Martine Bagot, Athanasios Tsianakas, Alison Moskowitz, Auris Huen, Brigitte Dreno, Stéphane Dalle, Dolores Caballero, Mollie Leoni, Stephen Dale, Fiona Herr, Madeleine Duvic
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: September 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 9Author(s): Eric C. Vonderheid, Jennifer Jakubowski, J. Steve Hou
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Eijiro Furukawa, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Anne Shah, Allison Petrilla, Mayvis Rebeira, Joseph Feliciano, Julie Lisano, Thomas W. LeBlanc
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Matthew R. Kudelka, Jeffrey M. Switchenko, Mary Jo Lechowicz, Natia Esiashvili, Christopher R. Flowers, Mohammad K. Khan, Pamela B. Allen
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This was a prescription claims-based analysis of the real-world treatment patterns, health care resource utilization, costs and survival outcomes in 2551 Medicare beneficiaries newly diagnosed with PTCL from 2011-2017. Data indicate significant use of resources prior to and following diagnosis, with no evident standard of care; survival outcomes at the time of analysis remained poor.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Angioimmunoblastic T-cell lymphoma (AITL) is a relatively rare but distinct histological subtype of peripheral T-cell lymphoma (PTCL), with a follicular helper T-cell origin, and is characterized by systemic symptoms, generalized lymphadenopathy, and hepatosplenomegaly.1 Pathologically, the neoplastic cells in AITL are present in a polymorphous inflammatory background. Irregular proliferation of follicular dendritic cells and proliferative high endothelial venules are also characteristic of AITL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
In this study, we found that CaMKIIγ was aberrantly activated in human MM and its expression level was positively correlated with malignant progression and poor prognosis. Ectopic expression of CaMKIIγ promoted cell growth, colony formation, cell cycle progress and inhibited apoptosis of MM cell lines, whereas, knockdown of CAMKIIγ expression suppressed MM cell growth in vitro and in vivo. Mechanically, we observed that CaMKIIγ overexpression upregulated p-ERK and p-Stat3 levels and suppression of CaMKIIγ had opposite effects. CaMKIIγ is frequently dysregulated in MM and plays a critical...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
More News: Cancer & Oncology | Chemotherapy | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants